RxDoctor Payments Data

Marissa Niemeyer

Gerontology · Grand Rapids, MINPI 1003485194

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 26 payments — averaging $45.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$341
  • Medtronic$241
  • Gilead$170
  • Neurocrine Biosciences, Inc.$94
  • Sanofi$86
  • Viatris Specialty LLC$70
  • plus $179 from 6 others

What the payments were for

  • Food & beverage$1,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 70th percentile of 279 gerontology providers in Michigan.

See all gerontology providers in Michigan

Medicare billing

Part B allowed, 2024
$115,006
Medicare patients
146
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate32$104,457
JardianceEmpagliflozin220$68,442
JanuviaSitagliptin Phosphate173$49,808
EliquisApixaban132$38,861
RexultiBrexpiprazole60$31,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$30,439
XtandiEnzalutamide14$24,858
TradjentaLinagliptin71$19,391
FarxigaDapagliflozin Propanediol66$19,207
TrulicityDulaglutide13$13,947
Bydureon BciseExenatide Microspheres35$13,691
XareltoRivaroxaban35$10,104
DapagliflozinDapagliflozin Propanediol26$7,299
Lacosamide73$6,193
Atorvastatin Calcium212$5,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$341$31,00160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 279 gerontology providers in Michigan.

Other gerontology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →